Whitehawk Therapeutics Inc WHWK.OQ WHWK.O is expected to show a rise in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025
The Morristown New Jersey-based company is expected to report a 362.2% increase in revenue to $33.333 million from $7.21 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Whitehawk Therapeutics Inc is for earnings of 7 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $2.00, about 12.5% below its last closing price of $2.25
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | 0.34 | 0.49 | -0.76 | Missed | -254.1 |
Mar. 31 2025 | -0.41 | -0.46 | -0.37 | Beat | 19.6 |
Dec. 31 2024 | -0.23 | -0.22 | -0.67 | Missed | -204.5 |
Sep. 30 2024 | -0.38 | -0.46 | -0.46 | Met | -0.5 |
Jun. 30 2024 | -0.69 | -0.69 | -0.54 | Beat | 21.7 |
Mar. 31 2024 | -0.63 | -0.64 | -0.68 | Missed | -5.8 |
Dec. 31 2023 | -0.65 | -0.60 | Beat | 7.4 | |
Sep. 30 2023 | -0.72 | -0.72 | -0.60 | Beat | 17.1 |
This summary was machine generated October 31 at 14:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)